Source: Health Policy, 2013
Authors: Jamie R. Daw, Steven G. Morgan, Paige A. Thomson, Michael R. Law
Canada is the only developed country that has established universal coverage for hospital care and physician services that excludes medically necessary prescription drugs. Lack of public... Read more
Source: Annals of Oncology, 2013
Authors: F. E. Vera-Badillo, R. Shapiro, A. Ocana, E. Amir, I. F. Tannock
Background Phase III randomized, clinical trials (RCTs) assess clinically important differences in end points that reflect benefit to patients. Here, we evaluate the quality of reporting of the... Read more
Source: BMC Health Services Research, 2013
Authors: Steve G Morgan, Paige A Thomson, Jamie R Daw, Melissa K Friesen
BackgroundConfidential product listing agreements (PLAs) negotiated between pharmaceutical manufacturers and individual health care payers may contribute to unwanted price disparities, high... Read more
Source: Archives of Internal Medicine, 2005
Authors: David Henry, Evan Doran, Ian Kerridge, Suzanne Hill, Paul M. McNeill, Richard Day
BackgroundIt is believed that pharmaceutical industry sponsorship of clinical research leads to the development of multiple ties between clinicians and the pharmaceutical industry. To quantify this... Read more
Source: Health Policy, 2012
Authors: Joel Lexchin
IntroductionThis study was undertaken to compare decisions about medicines innovation made by two Canadian organizations, the Therapeutic Products Directorate (TPD) and the Human Drug Advisory Panel... Read more
Source: Review of Industrial Organization, 2005
Authors: Aidan Hollis
This paper examines the price effects of generic drugs that are produced by brand-name drug firms and that are labeled, priced, and marketed to compete against independent generics. The strategy of... Read more
Steve Morgan
Michael Law
David Henry
Joel Lexchin
Aidan Hollis